Clinical Trial Update: Extension Study to Evaluate Safety and Efficacy of Jaktinib in Patients With Active Ankylosing Spondylitis(AS) [Phase 3]

View source ↗

Summary

Extension study update for Jaktinib in active Ankylosing Spondylitis in Phase 3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis

Drugs mentioned

• Jaktinib (jaktinib)

Snippet

Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd | Conditions: Ankylosing Spondylitis | Phase 3 | Status: UNKNOWN